Figure 2.
SH-BC-893 enhances oligonucleotide activity. (A) MALAT1 levels in HeLa cells treated with the indicated concentrations of 3–10–3 cEt gapmer targeting MALAT1 ± SH-BC-893 (5 μM) for 24 h. Mean ± SD shown, n = 6. (B) IC50s from each biological replicate in (A); mean ± SD shown. Using a Welch's t test to correct for unequal SD, ***P < 0.001. (C, D) As in (A, B), except using a 5–10–5 2’MOE gapmer; mean ± SD shown, n = 3. Using a Welch's t test to correct for unequal SD’s, **P < 0.01. (E) As in (A), except data expressed relative to total RNA or to housekeeping gene ACTB, n = 1. (F) As in (A), except with indicated concentrations of 893, n = 1. (G) As in (A), except using a 3–10–3 cEt gapmer targeting the ACTN1 mRNA and n = 3. IC50 values for control could not be calculated due to the low basal activity of this ASO. (H) The indicated cell lines were treated with the cEt MALAT1 ASO ± SH-BC-893 (5 μM) for 24 h and an IC50 (nM) calculated. Dose response curves shown in Supplementary Figure S5. (I) HPRT1 mRNA levels in HeLa cells treated with the indicated doses of a palmitate-conjugated siRNA targeting HPRT1 ± SH-BC-893 (5 μM) for 24 h. Mean ± SD shown, n = 3. (J) IC50s from each biological replicate in (I); mean ± SD shown. Using a Welch's t test to correct for unequal SD, ***P < 0.001.